GlaxoSmithKline PLC at Barclays Global Healthcare Conference (Virtual) Transcript
Sorry, I was muted there. Welcome, everybody. My name is Emily Field. I am the European Pharmaceuticals Analyst here at Barclays. And we are delighted to be hosting, from GSK, the CEO of ViiV Healthcare, Deborah Waterhouse. And Deborah will provide a few opening remarks before we get into a Q&A fireside chat style.
So Deborah, over to you.
Thanks, Emily. Thanks for inviting me to do this fireside chat today. So just a few opening comments. So 2020 was a strong year for ViiV Healthcare in terms of innovation, performance and our trust objectives. We delivered 1% growth in the year, and that was accelerated in quarter 4 to 2% top line growth.
We have just been through 2 years of the business being broadly flat. And I'm delighted to be able to say that we're now moving back to progressive acceleration in growth, and that's really underpinned by the continued expansion of our 2-drug regimen portfolio,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
